Item 7.01 Regulation FD Disclosure.
On March 6, 2023, BioCardia, Inc. (the “Company”) issued a press release
announcing that detailed echocardiography data from the roll-in cohort of its
Phase III CardiAMP© Cell Therapy Heart Failure Trial (ClinicalTrials.gov
Identifier: NCT02438306) will be presented at the American College of Cardiology
Annual Meeting later that same day. A copy of the press release is attached
hereto as Exhibit 99.1 to this current report on Form 8-K.
The information furnished pursuant to this Item 7.01, including Exhibit 99.1
hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities under that section, nor shall it be deemed to be incorporated by
reference in any filing made by the Company under the Securities Act of 1933, as
amended, or the Exchange Act, except as otherwise expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 BioCardia, Inc. press release dated March 6, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
——————————————————————————–
© Edgar Online, source Glimpses
postbrexitcompliance.com 